Ilona Krol

3.9k total citations · 4 hit papers
13 papers, 2.6k citations indexed

About

Ilona Krol is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Ilona Krol has authored 13 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Cancer Research. Recurrent topics in Ilona Krol's work include Cancer Cells and Metastasis (8 papers), Cancer Genomics and Diagnostics (3 papers) and interferon and immune responses (2 papers). Ilona Krol is often cited by papers focused on Cancer Cells and Metastasis (8 papers), Cancer Genomics and Diagnostics (3 papers) and interferon and immune responses (2 papers). Ilona Krol collaborates with scholars based in Switzerland, United States and Italy. Ilona Krol's co-authors include Nicola Aceto, Barbara M. Szczerba, Francesc Castro-Giner, Viola Heinzelmann‐Schwarz, Marcus Vetter, Christoph Rochlitz, Christian Kurzeder, William P. Weber, Sofia Gkountela and Ramona Scherrer and has published in prestigious journals such as Nature, Cell and Journal of Clinical Investigation.

In The Last Decade

Ilona Krol

13 papers receiving 2.6k citations

Hit Papers

Neutrophils escort circulating tumour cells to enable cel... 2019 2026 2021 2023 2019 2019 2019 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neutrophils escort circulating tumour cells to enable cell cycle progression
    2019 886 citations Barbara M. Szczerba, Francesc Castro-Giner et al. Nature profile →
  2. Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding
    2019 608 citations Sofia Gkountela, Francesc Castro-Giner et al. Cell profile →
  3. E-cadherin is required for metastasis in multiple models of breast cancer
    2019 562 citations Veena Padmanaban, Ilona Krol et al. Nature profile →
  4. The metastatic spread of breast cancer accelerates during sleep
    2022 180 citations Zoi Diamantopoulou, Francesc Castro-Giner et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ilona Krol Switzerland 12 1.5k 1.0k 969 500 415 13 2.6k
Shetal Patel United States 18 842 0.6× 1.4k 1.4× 1.2k 1.2× 596 1.2× 320 0.8× 40 3.0k
Jiha Kim United States 15 1.4k 0.9× 1.6k 1.6× 850 0.9× 351 0.7× 242 0.6× 35 2.8k
Maja H. Oktay United States 32 1.7k 1.1× 1.5k 1.5× 854 0.9× 893 1.8× 447 1.1× 84 3.5k
Krisztián Homicskó Switzerland 26 1.4k 0.9× 926 0.9× 447 0.5× 566 1.1× 394 0.9× 69 2.7k
Antonija Kreso Canada 11 1.9k 1.3× 2.2k 2.1× 1.3k 1.3× 407 0.8× 226 0.5× 11 3.7k
María Soledad Sosa United States 21 1.6k 1.1× 1.4k 1.4× 908 0.9× 501 1.0× 223 0.5× 32 2.9k
Yi‐Fang Ping China 34 1.4k 0.9× 1.9k 1.9× 1.2k 1.2× 929 1.9× 277 0.7× 70 3.7k
Nicole M. Aiello United States 11 2.1k 1.4× 1.8k 1.8× 1.2k 1.3× 377 0.8× 297 0.7× 15 3.6k
Xiaoguang Fang United States 22 1.1k 0.7× 2.0k 2.0× 1.2k 1.3× 723 1.4× 217 0.5× 22 3.4k
Zhenhe Suo Norway 32 1.3k 0.8× 1.8k 1.8× 872 0.9× 273 0.5× 187 0.5× 107 3.1k

Countries citing papers authored by Ilona Krol

Since Specialization
Citations

This map shows the geographic impact of Ilona Krol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilona Krol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilona Krol more than expected).

Fields of papers citing papers by Ilona Krol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilona Krol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilona Krol. The network helps show where Ilona Krol may publish in the future.

Co-authorship network of co-authors of Ilona Krol

This figure shows the co-authorship network connecting the top 25 collaborators of Ilona Krol. A scholar is included among the top collaborators of Ilona Krol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilona Krol. Ilona Krol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Schwab, Fabienne D., Manuel C. Scheidmann, André Kling, et al.. (2022). MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies. Microsystems & Nanoengineering. 8(1). 130–130. 17 indexed citations
2.
Diamantopoulou, Zoi, Francesc Castro-Giner, Fabienne D. Schwab, et al.. (2022). The metastatic spread of breast cancer accelerates during sleep. Nature. 607(7917). 156–162. 180 indexed citations breakdown →
3.
Scheidmann, Manuel C., Francesc Castro-Giner, Karin Strittmatter, et al.. (2021). An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression. Cancer Research. 82(4). 681–694. 18 indexed citations
4.
Weth, Agnes, Ilona Krol, Cinzia Donato, et al.. (2020). A novel device for elimination of cancer cells from blood specimens. Scientific Reports. 10(1). 10181–10181. 11 indexed citations
5.
Padmanaban, Veena, Ilona Krol, Yasir Suhail, et al.. (2019). E-cadherin is required for metastasis in multiple models of breast cancer. Nature. 573(7774). 439–444. 562 indexed citations breakdown →
6.
Szczerba, Barbara M., Francesc Castro-Giner, Marcus Vetter, et al.. (2019). Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 566(7745). 553–557. 886 indexed citations breakdown →
7.
Gkountela, Sofia, Francesc Castro-Giner, Barbara M. Szczerba, et al.. (2019). Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. Cell. 176(1-2). 98–112.e14. 608 indexed citations breakdown →
8.
Krol, Ilona, Francesc Castro-Giner, Martina Maurer, et al.. (2018). Detection of circulating tumour cell clusters in human glioblastoma. British Journal of Cancer. 119(4). 487–491. 102 indexed citations
9.
Vetter, Marcus, Julia Landin, Barbara M. Szczerba, et al.. (2018). Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer. Breast Cancer Research. 20(1). 141–141. 25 indexed citations
10.
Bernsmeier, Christine, Michael T. Dill, A. Provenzano, et al.. (2016). Hepatic Notch1 deletion predisposes to diabetes and steatosis via glucose-6-phosphatase and perilipin-5 upregulation. Laboratory Investigation. 96(9). 972–980. 16 indexed citations
11.
Król, Jacek, Ilona Krol, Michele Fiscella, et al.. (2015). A network comprising short and long noncoding RNAs and RNA helicase controls mouse retina architecture. Nature Communications. 6(1). 7305–7305. 70 indexed citations
12.
Duong, François H.T., Gaia Trincucci, Tujana Boldanova, et al.. (2014). IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. The Journal of Experimental Medicine. 211(5). 857–868. 52 indexed citations
13.
Dill, Michael T., Zuzanna Makowska, Gaia Trincucci, et al.. (2014). Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. Journal of Clinical Investigation. 124(4). 1568–1581. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shetal Patel Breakdown of academic impact, for papers by Jiha Kim Breakdown of academic impact, for papers by Maja H. Oktay Breakdown of academic impact, for papers by Krisztián Homicskó Breakdown of academic impact, for papers by Antonija Kreso Breakdown of academic impact, for papers by María Soledad Sosa Breakdown of academic impact, for papers by Yi‐Fang Ping Breakdown of academic impact, for papers by Nicole M. Aiello Breakdown of academic impact, for papers by Xiaoguang Fang Breakdown of academic impact, for papers by Zhenhe Suo
Rankless by CCL
2026